Zydus Therapeutics reports positive phase-3 results in rare liver disease
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Delegates also visited Emami’s WHO-GMP-certified manufacturing plant and Zandu Foundation for Healthcare farms for hands-on exposure to quality practices,
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Subscribe To Our Newsletter & Stay Updated